The Benign Course of PLS
A Strong Point in Favor of an Earlier Differentiation From ALS
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published February 26, 2021.
Article Versions
- Previous version (February 26, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Federica Agosta, MD, PhD and
- Massimo Filippi, MD, FEAN, FAAN
- Federica Agosta, MD, PhD and
NONE
NONE
Biogen, Roche, Philips: speaker honoraria
(1) NeuroImage-Clinical, Section Editor, 2016-present (2) Frontiers in Neurology  Applied Neuroimaging, Associate Editor, 2017-present (3) Journal of Neurology, member of the Editorial Board, 2012-present (4) Journal of Neuroimaging, member of the Editorial Board, 2015-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Research Council, NeuroTRACK Principal Investigator, 2017-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Filippi, MD, FEAN, FAAN
NONE
NONE
Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries
Editor-in-Chief (2012-present), Journal of Neurology; Associate Editor, Neurological Sciences (2016-present); Associate Editor, Human Brain Mapping (since 2020)
NONE
NONE
NONE
Biogen Idec, Merck-Serono, Novartis
Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries
NONE
NONE
1) Commercial entity: Bayer 2) Commercial entity: Biogen-Idec 3) Commercial entity: Merck-Serono 4) Commercial entity: Novartis 5) Commercial entity: Roche 6) Commercial entity: Teva Pharmaceutical Industries
1) Italian Ministry of Health; grant number: GR-2013- 02357415; role: co-investigator; duration: September 2016-December 2020 2) Italian Ministry of Health; grant number: RF-2018- 12366746; role: PI; duration: 15/06/2020 Â 14/06/2023
NONE
1) Fondazione Italiana Sclerosi Multipla (FISM) 2) ARiSLA (Fondazione Italiana di Ricerca per la SLA)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimaging Research Unit, Division of Neuroscience, and Neurology Unit, Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute; and Vita-Salute San Raffaele University, Milan, Italy.
- Correspondence
Dr. Agosta agosta.federica{at}hsr.it
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan